Florian M E Wagenlehner1, Stefania Ballarini, Kurt G Naber. 1. Clinic for Urology, Pediatric Urology and Andrology, Justus-Liebig-University Giessen, Rudolf-Buchheim-Str. 7, 35385, Giessen, Germany, Wagenlehner@AOL.com.
Abstract
PURPOSE:Inflammation/immunological dysfunction are discussed etiological causes of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). OM-89 is an orally immunostimulating agent. We performed a phase three multicentre, randomized, double-blind, placebo-controlled, long-term (12 months) study with OM-89 produced with a different lysis process in patients with moderate-to-severe CP/CPPS type III. METHODS: Patients were randomized to OM-89 or placebo. Primary efficacy variable was difference of responders at the end of treatment (month 9) in patients receiving OM-89 versus placebo. RESULTS:Two hundred and three patients were screened, 185 patients (47.8 ± 8.4 years) (90 % of CP/CPPS type IIIb) were enrolled in 30 centers and included in the safety set. Ninety-four were randomized to OM-89, 91 toplacebo. One hundred and seventy-six patients were subjected to the full analysis (FAS), 150 to the per protocol set (PPS). Baseline NIH-CPSI score in FAS was 21.8 ± 3.8 (OM-89) and 23.0 ± 5.6 (placebo). At primary efficacy endpoint (month 9), in the OM-89 group, 67.0 % in FAS (PPS 72.7 %) and in the placebo group, 64.3 % in FAS (PPS 64.4 %) were responders [FAS: OR 1.19, p = 0.59; PPS: p = 0.19]. Mean relative decrease in NIH-CPSI was 40.5 and 44.0 % in the FAS. Treatment-related adverse events were low: 8.5 % with OM-89 and 5.5 % with placebo. Because of small numbers, no conclusion could be drawn regarding the potential benefit of OM-89 in CP/CPPS IIIa. CONCLUSIONS: This placebo-controlled study evaluating OM-89 in patients with CP/CPPS showed a significant and long-lasting (12 months) favorable response with OM-89, but also with placebo. OM-89 was safe and well tolerated. EUDRACT: 2007-004609-85.
RCT Entities:
PURPOSE: Inflammation/immunological dysfunction are discussed etiological causes of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). OM-89 is an orally immunostimulating agent. We performed a phase three multicentre, randomized, double-blind, placebo-controlled, long-term (12 months) study with OM-89 produced with a different lysis process in patients with moderate-to-severe CP/CPPS type III. METHODS:Patients were randomized to OM-89 or placebo. Primary efficacy variable was difference of responders at the end of treatment (month 9) in patients receiving OM-89 versus placebo. RESULTS: Two hundred and three patients were screened, 185 patients (47.8 ± 8.4 years) (90 % of CP/CPPS type IIIb) were enrolled in 30 centers and included in the safety set. Ninety-four were randomized to OM-89, 91 to placebo. One hundred and seventy-six patients were subjected to the full analysis (FAS), 150 to the per protocol set (PPS). Baseline NIH-CPSI score in FAS was 21.8 ± 3.8 (OM-89) and 23.0 ± 5.6 (placebo). At primary efficacy endpoint (month 9), in the OM-89 group, 67.0 % in FAS (PPS 72.7 %) and in the placebo group, 64.3 % in FAS (PPS 64.4 %) were responders [FAS: OR 1.19, p = 0.59; PPS: p = 0.19]. Mean relative decrease in NIH-CPSI was 40.5 and 44.0 % in the FAS. Treatment-related adverse events were low: 8.5 % with OM-89 and 5.5 % with placebo. Because of small numbers, no conclusion could be drawn regarding the potential benefit of OM-89 in CP/CPPS IIIa. CONCLUSIONS: This placebo-controlled study evaluating OM-89 in patients with CP/CPPS showed a significant and long-lasting (12 months) favorable response with OM-89, but also with placebo. OM-89 was safe and well tolerated. EUDRACT: 2007-004609-85.
Authors: Florian M E Wagenlehner; J W Olivier van Till; Vittorio Magri; Gianpaolo Perletti; Jos G A Houbiers; Wolfgang Weidner; J Curtis Nickel Journal: Eur Urol Date: 2012-11-02 Impact factor: 20.096
Authors: M S Litwin; M McNaughton-Collins; F J Fowler; J C Nickel; E A Calhoun; M A Pontari; R B Alexander; J T Farrar; M P O'Leary Journal: J Urol Date: 1999-08 Impact factor: 7.450
Authors: Mary P Fitzgerald; Rodney U Anderson; Jeannette Potts; Christopher K Payne; Kenneth M Peters; J Quentin Clemens; Rhonda Kotarinos; Laura Fraser; Annemarie Cosby; Carole Fortman; Cynthia Neville; Suzanne Badillo; Lisa Odabachian; Andrea Sanfield; Betsy O'Dougherty; Rick Halle-Podell; Liyi Cen; Shannon Chuai; J Richard Landis; Keith Mickelberg; Ted Barrell; John W Kusek; Leroy M Nyberg Journal: J Urol Date: 2013-01 Impact factor: 7.600
Authors: Dominik S Schoeb; Daniel Schlager; Martin Boeker; Ulrich Wetterauer; Martin Schoenthaler; Thomas R W Herrmann; Arkadiusz Miernik Journal: World J Urol Date: 2017-06-13 Impact factor: 4.226
Authors: Igor Gorpynchenko; Kamil Nurimanov; Tatiana Poroshina; Viktoria Savchenko; George Drannik; Alexander Shulyak Journal: Cent European J Urol Date: 2021-05-07